- Home
- FLYW vs AUPH Comparison
FLYW vs AUPH Comparison
Compare FLYW & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- AUPH
- Stock Information
- Founded
- FLYW 2009
- AUPH 1993
- Country
- FLYW United States
- AUPH Canada
- Employees
- FLYW N/A
- AUPH N/A
- Industry
- FLYW Computer Software: Prepackaged Software
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- FLYW Technology
- AUPH Health Care
- Exchange
- FLYW Nasdaq
- AUPH Nasdaq
- Market Cap
- FLYW 1.5B
- AUPH 1.4B
- IPO Year
- FLYW 2021
- AUPH 1999
- Fundamental
- Price
- FLYW $13.29
- AUPH $12.84
- Analyst Decision
- FLYW Buy
- AUPH Strong Buy
- Analyst Count
- FLYW 14
- AUPH 3
- Target Price
- FLYW $14.54
- AUPH $12.00
- AVG Volume (30 Days)
- FLYW 1.9M
- AUPH 1.6M
- Earning Date
- FLYW 11-06-2025
- AUPH 11-06-2025
- Dividend Yield
- FLYW N/A
- AUPH N/A
- EPS Growth
- FLYW N/A
- AUPH N/A
- EPS
- FLYW 0.05
- AUPH 0.42
- Revenue
- FLYW $539,708,000.00
- AUPH $260,111,000.00
- Revenue This Year
- FLYW $20.28
- AUPH $16.92
- Revenue Next Year
- FLYW $15.67
- AUPH $14.43
- P/E Ratio
- FLYW $263.61
- AUPH $30.31
- Revenue Growth
- FLYW 22.20
- AUPH 25.59
- 52 Week Low
- FLYW $8.20
- AUPH $6.43
- 52 Week High
- FLYW $23.40
- AUPH $12.87
- Technical
- Relative Strength Index (RSI)
- FLYW 61.16
- AUPH 68.38
- Support Level
- FLYW $12.77
- AUPH $12.06
- Resistance Level
- FLYW $14.02
- AUPH $12.82
- Average True Range (ATR)
- FLYW 0.44
- AUPH 0.37
- MACD
- FLYW -0.01
- AUPH -0.04
- Stochastic Oscillator
- FLYW 49.63
- AUPH 92.30
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.